Printer Friendly

UNIMED ANNOUNCES APPROVAL OF MARINOL EFFICACY SUPPLEMENT BY FOOD AND DRUG ADMINISTRATION

 BUFFALO GROVE, Ill., Dec. 22 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that the U.S. Food and Drug Administration (FDA) has approved the use of its MARINOL(R) product in the treatment of anorexia associated with weight loss patients with Acquired Immune Deficiency Syndrome (AIDS). MARINOL is the first drug approved by the FDA that specifically targets AIDS-related anorexia associated with weight loss, a common manifestation of the disease. The FDA first approved the use of MARINOL in 1985 as an antiemetic product for cancer chemotherapy patients. The effectiveness of MARINOL as an antiemetic has been documented in 28 published studies involving approximately 3,000 cancer patients with high response rates even in patients refractory to first-line drugs.
 UNIMED filed a Supplemental New Drug Application (SNDA) with the FDA earlier this year following the completion of a Phase III double-blind Placebo-controlled trial of MARINOL for appetite stimulation and prevention of anorexia associated with weight loss in patients with AIDS. The positive results of that trial, along with other studies, formed the basis if the SNDA which the FDA approved today.
 "We are extremely excited about this application for MARINOL," said UNIMED Senior Vice President of Sales and Marketing, Scott Broder, "which offers a means for AIDS patients to enhance the quality of their lives. There is wide-spread agreement on the positive role that a nutritional regimen plays in the health of AIDS patients and it is our belief that MARINOL, as an appetite stimulant, can be of great value."
 The active ingredient of MARINOL is a synthetic marijuana agent called delta-9-tetrahydrocannibinol (THC). MARINOL must be prescribed by a physician and is taken in capsule form.
 In the United States, MARINOL is comarketed by UNIMED with Roxane Laboratories, Inc., of Columbus, Ohio, a member of the Boehringer Ingelheim group of companies.
 UNIMED, Inc., headquartered in Buffalo Grove, Ill., is a publicly traded company which specializes in the development and commercialization of products which enhance the quality of life for immuno-suppressed individuals. These products help in alleviating symptoms resulting from lowered immunity thereby helping patients feel better. UNIMED's product portfolio includes MucoCare, NutraCare and skin care products that provide quality of life benefits for immuno- suppressed individuals.
 -0- 12/22/92
 /CONTACT: Scott Broder, senior vice president of sales and marketing, or David Riggs, vice president of finance, both of UNIMED Inc., 708-541-2525; or Lloyd Benson or Gilly Weinstein of Cudaback Strategic Communications, 617-661-6330, for UNIMED/
 (UMED)


CO: UNIMED, Inc. ST: Illinois, Ohio IN: MTC HEA SU: PDT

TM -- NE005 -- 9136 12/22/92 12:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 22, 1992
Words:426
Previous Article:AULT REPORTS SECOND QUARTER EARNINGS
Next Article:KENDALL INTERNATIONAL, INC. ANNOUNCES REFINANCING PLAN
Topics:


Related Articles
UNIMED SIGNS LICENSE AGREEMENT FOR DISTRIBUTION OF MARINOL IN SOUTH KOREA
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED GAINS INVESTMENT SUPPORT FOR EUROPEAN DEVELOPMENT OF MARINOL IN NEW COLLABORATION AGREEMENT
UNIMED HITS ENROLLMENT TARGET FOR MARINOL PHASE III STUDIES IN AIDS PATIENTS
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
UNIMED INTRODUCES MARINOL IN AUSTRALIA AND PUERTO RICO
UNIMED'S MARINOL FOUND PROMISING IN TREATING CONDITIONS RELATED TO ALZHEIMER'S DISEASE
Unimed Announces Approval And Launch Of Marinol In South Africa
Drug with Active Marijuana Ingredient Available Through Medical Channels
Legal Drug With Active Marijuana Ingredient Available Through Medical Channels

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters